PL1622939T3 - Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania - Google Patents

Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania

Info

Publication number
PL1622939T3
PL1622939T3 PL04739182T PL04739182T PL1622939T3 PL 1622939 T3 PL1622939 T3 PL 1622939T3 PL 04739182 T PL04739182 T PL 04739182T PL 04739182 T PL04739182 T PL 04739182T PL 1622939 T3 PL1622939 T3 PL 1622939T3
Authority
PL
Poland
Prior art keywords
binding protein
medical uses
active variants
active fragments
active
Prior art date
Application number
PL04739182T
Other languages
English (en)
Inventor
Valter Marino Altarocca
Anna R Pezzotti
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of PL1622939T3 publication Critical patent/PL1622939T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
PL04739182T 2003-05-13 2004-05-11 Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania PL1622939T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03101326 2003-05-13
EP04739182A EP1622939B1 (en) 2003-05-13 2004-05-11 Active variants of the il-18 binding protein and medical uses thereof
PCT/EP2004/005073 WO2004101617A1 (en) 2003-05-13 2004-05-11 Active variants of the il-18 binding protein and medical uses thereof

Publications (1)

Publication Number Publication Date
PL1622939T3 true PL1622939T3 (pl) 2012-08-31

Family

ID=33442815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04739182T PL1622939T3 (pl) 2003-05-13 2004-05-11 Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania

Country Status (16)

Country Link
US (2) US20080076708A1 (pl)
EP (1) EP1622939B1 (pl)
JP (1) JP5074030B2 (pl)
AT (1) ATE549353T1 (pl)
AU (1) AU2004238524B2 (pl)
CA (1) CA2524403C (pl)
CY (1) CY1112682T1 (pl)
DK (1) DK1622939T3 (pl)
ES (1) ES2384241T3 (pl)
HR (1) HRP20120246T1 (pl)
IL (1) IL171914A (pl)
NO (1) NO338682B1 (pl)
PL (1) PL1622939T3 (pl)
PT (1) PT1622939E (pl)
SI (1) SI1622939T1 (pl)
WO (1) WO2004101617A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
CA2541523A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) * 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ATE375385T1 (de) * 2004-03-01 2007-10-15 Ares Trading Sa Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
US7557084B2 (en) 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
ES2313367T3 (es) 2004-06-29 2009-03-01 Ares Trading S.A. Procedimiento para la purificacion de proteina de union al il-18.
WO2006128911A2 (en) * 2005-06-03 2006-12-07 Laboratoires Serono S.A. Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases
CA2609060C (en) * 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
JP2014506889A (ja) 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
JP7795181B2 (ja) * 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン－１８バリアントとその利用法
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
CA2407895C (en) 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
IL157024A0 (en) 2001-01-29 2004-02-08 Applied Research Systems Il-18 inhibitors in heart disease
BR0210904A (pt) 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
US7655616B2 (en) 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
EA006881B1 (ru) 2001-10-11 2006-04-28 Апплайд Резеч Системз Арс Холдинг Н.В. ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
CA2541523A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) * 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
ATE375385T1 (de) * 2004-03-01 2007-10-15 Ares Trading Sa Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
ES2313367T3 (es) * 2004-06-29 2009-03-01 Ares Trading S.A. Procedimiento para la purificacion de proteina de union al il-18.
CA2609060C (en) * 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) * 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18

Also Published As

Publication number Publication date
CY1112682T1 (el) 2016-02-10
IL171914A (en) 2013-05-30
CA2524403A1 (en) 2004-11-25
JP2007535903A (ja) 2007-12-13
AU2004238524B2 (en) 2011-06-23
EP1622939B1 (en) 2012-03-14
JP5074030B2 (ja) 2012-11-14
PT1622939E (pt) 2012-03-28
ES2384241T3 (es) 2012-07-02
NO20055838D0 (no) 2005-12-08
DK1622939T3 (da) 2012-04-10
CA2524403C (en) 2013-07-09
ATE549353T1 (de) 2012-03-15
NO338682B1 (no) 2016-09-26
WO2004101617A1 (en) 2004-11-25
SI1622939T1 (sl) 2012-06-29
EP1622939A1 (en) 2006-02-08
AU2004238524A1 (en) 2004-11-25
US20110189131A1 (en) 2011-08-04
IL171914A0 (en) 2006-04-10
HRP20120246T1 (hr) 2012-04-30
NO20055838L (no) 2006-02-13
US20080076708A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
SI1622939T1 (sl) Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004041269A3 (en) New use for pharmaceutical composition
TW200716646A (en) (S)-N-methylnaltrexone
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
TW200505875A (en) Novel compounds
TWI340138B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
TW200508214A (en) Novel compounds
WO2003072593A3 (en) Bone targeting peptides
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
AU2003236156A1 (en) Pharmaceutical compositions used for immune disease treatment and improvement
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
WO2007134118A3 (en) Protein based composition and methods of using same
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2004026892A3 (en) Fragmentation of dna
PL361364A1 (pl) Peptyd i kompozycja farmaceutyczna oraz ich zastosowania medyczne
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2006023465A8 (en) Polyethylene glycol-peptide copper complexes and compositions and methods related thereto
WO2006103354A3 (fr) Composition dermatologique et/ou cosmetique contenant des proteines de la famille des sirt